<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074630</url>
  </required_header>
  <id_info>
    <org_study_id>METC AMC 2016_016</org_study_id>
    <nct_id>NCT03074630</nct_id>
  </id_info>
  <brief_title>Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)</brief_title>
  <acronym>DICE</acronym>
  <official_title>Dapagliflozin on Cholesterol Metabolism in DM2: Dissecting Its Effect on Dyslipidemia by Using Stable Isotope Based Cholesterol and Glucose Fluxes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To investigate the effect of 5 weeks dapagliflozin 10 mg once daily treatment on&#xD;
      glucose and lipid fluxes in patients with type 2 diabetes.&#xD;
&#xD;
      Study design: Single center single arm (mechanistic) intervention trial.&#xD;
&#xD;
      Study Population: Male or postmenopausal female patients with type 2 diabetes BMI &gt; 25&#xD;
      kg/m2and more than 12 weeks a stable dose of metformin treatment &gt; 1500mg, HbA1C ≥6.5% -&#xD;
      &lt;8.5%, Fasting Plasma Glucose (FPG) &lt;13.2 mmol/l, LDL cholesterol &gt;2.5 mmol/l, willing to&#xD;
      switch to rosuvastatin 10mg once daily for 4 weeks, and then receive 10 mg dapagliflozin once&#xD;
      daily orally, for 5 weeks.&#xD;
&#xD;
      Treatment: After a statin washout fase of 4 weeks, baseline cholesterol synthesis will be&#xD;
      measured (2H3 Leucine, 2H2O deuterated water). Then, treatment with rosuvastatin 10mg for 4&#xD;
      weeks will be initiated after which, patients will undergo glucose (2H2enriched glucose) and&#xD;
      lipid flux (2H3 Leucine, 2H2O deuterated water and oral 1,2,3,4-13C16 - palmitate enrichment&#xD;
      measurements) followed by 5 weeks treatment with dapagliflozin 10mg once daily. In the final&#xD;
      week glucose/lipid flux measurements will be repeated.&#xD;
&#xD;
      Sample Size: 12 DM2 subjects.&#xD;
&#xD;
      Outcome measures: The primary endpoint is effect of 5 weeks Sodium-Glucose Linked&#xD;
      co-transporter (SGLT) 2 inhibition on LDL cholesterol synthesis in patients with DM2.&#xD;
      Secondary endpoints are effect of SGLT2 inhibition on triglyceride and cholesterol fluxes as&#xD;
      well as (hepatic and peripheral) insulin sensitivity and energy expenditure. Finally, effect&#xD;
      of SGLT2 inhibition on dietary intake, liver fat content (MRI liver) and fecal microbiome&#xD;
      will be studied at these timepoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Type 2 diabetes is associated with an increased cardiovascular risk. Besides&#xD;
      metformin, a new treatment strategy is oral SGLT2 inhibition (dapagliflozin), Although the&#xD;
      recently published, first-in-class cardiovascular outcome trial (EMPA-REG OUTCOME) has&#xD;
      suggested a beneficial effect on all cause cardiovascular mortality upon SGLT2 inhibition, a&#xD;
      known (class) side effect in worsening of dyslipidemia in all DM2 patients. The investigators&#xD;
      thus aim to dissect the effect of SGLT2 inhibition (Dapagliflozin 10mg once daily for 5&#xD;
      weeks) on glucose and lipid fluxes in uncomplicated DM2 subjects.&#xD;
&#xD;
      Objective: To investigate the effect of 5 weeks dapagliflozin 10 mg once daily treatment on&#xD;
      glucose and lipid fluxes in patients with type 2 diabetes.&#xD;
&#xD;
      Study design: Single center single arm (mechanistic) intervention trial.&#xD;
&#xD;
      Study Population: Male or postmenopausal female patients with type 2 diabetes BMI &gt; 25&#xD;
      kg/m2and more than 12 weeks a stable dose of metformin treatment &gt; 1500mg, HbA1C ≥6.5% -&#xD;
      &lt;8.5%, FPG&lt;13.2 mmol/l, LDL cholesterol &gt;2.5 mmol/l, willing to switch to rosuvastatin 10mg&#xD;
      once daily for 4 weeks, and then receive 10 mg dapagliflozin once daily orally, for 5 weeks.&#xD;
&#xD;
      Treatment: After a statin washout fase of 4 weeks, baseline cholesterol synthesis will be&#xD;
      measured (2H3 Leucine, 2H2O deuterated water). Then, treatment with rosuvastatin 10mg for 4&#xD;
      weeks will be initiated after which, patients will undergo glucose (2H2enriched glucose) and&#xD;
      lipid flux (2H3 Leucine, 2H2O deuterated water and oral 1,2,3,4-13C16 - palmitate enrichment&#xD;
      measurements) followed by 5 weeks treatment with dapagliflozin 10mg once daily. In the final&#xD;
      week glucose/lipid flux measurements will be repeated.&#xD;
&#xD;
      Outcome measures: The primary endpoint is effect of 5 weeks SLGT2 inhibition on LDL&#xD;
      cholesterol synthesis in patients with DM2. Secondary endpoints are effect of SGLT2&#xD;
      inhibition on triglyceride and cholesterol fluxes as well as (hepatic and peripheral) insulin&#xD;
      sensitivity and energy expenditure. Finally, effect of SGLT2 inhibition on dietary intake,&#xD;
      liver fat content (MRI liver) and fecal microbiome will be studied at these timepoints.&#xD;
&#xD;
      Sample Size: Based on published data, the investigators expect 10% higher plasma LDL level&#xD;
      (from 3.1 ± 0.8 to 1.7 ± 0.4 mmol/l ) upon SGLT2 inhibition in DM2. DM2 subjects have&#xD;
      concomitant LDL- ApoB synthesis (1.8 ± 0.4 gram/day) after 4 weeks of rosuvastatin 10mg.&#xD;
      Assuming an increase in LDL-apoB synthesis of 0.3 gram/day with SD of 0.4 and using&#xD;
      single-sided test (with alfa of 0.05 and 85% power), the sample size needs to be 11 DM2&#xD;
      subjects on dapagliflozin 10mg treatment. Taking a 10% patient dropout rate, the aim is to&#xD;
      include 12 DM2 subjects in total.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: The risk for patients to participate in this study is minimal. All of the stable&#xD;
      isotopes are GMP produced and analyses techniques have been previously used and published by&#xD;
      the investigators. Also, REE and liver MRI measurements are not associated with adverse&#xD;
      events. Both rosuvastatin and dapagliflozin have been approved by FDA/EMA and are widely&#xD;
      prescribed. In total 470 ml blood (100 ml per lipidflux day, 90 ml per clamp day) will be&#xD;
      drawn over period of 13 weeks (divided over 5 visits).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma LDL Cholesterol</measure>
    <time_frame>5 weeks</time_frame>
    <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma HDL Cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in plasma HDL cholesterol following dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol</measure>
    <time_frame>5 weeks</time_frame>
    <description>Change in total cholesterol following dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Triglycerides</measure>
    <time_frame>5 weeks</time_frame>
    <description>Change in plasma Triglycerides following dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma FFA</measure>
    <time_frame>5 weeks</time_frame>
    <description>Change in plasma FFA following dapagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cholesterol Fluxes</measure>
    <time_frame>5 weeks</time_frame>
    <description>Including cholesterol production, cholesterol excretion, cholesterol degradation. Before and after 5 weeks of dapagliflozin on rosuvastatin background.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglyceride Fluxes</measure>
    <time_frame>5 weeks</time_frame>
    <description>Including cholesterol production, cholesterol excretion, cholesterol degradation. Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peripheral Insulin Sensitivity</measure>
    <time_frame>5 weeks</time_frame>
    <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background, measured as glucose disposal during hyperinsulinemic euglycemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Fat MRI Spectrum</measure>
    <time_frame>5 weeks</time_frame>
    <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Microbiome Composition</measure>
    <time_frame>5 weeks</time_frame>
    <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background, different bacterial strains will be quantified in fresh fecal samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile Salt Excretion</measure>
    <time_frame>5 weeks</time_frame>
    <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion</measure>
    <time_frame>5 weeks</time_frame>
    <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Sodium Excretion</measure>
    <time_frame>5 weeks</time_frame>
    <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10mg and Rosuvastatin 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>5 weeks 10mg dapagliflozin once daily</description>
    <arm_group_label>Dapagliflozin 10mg and Rosuvastatin 10mg</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>9 weeks 10mg dapagliflozin once daily</description>
    <arm_group_label>Dapagliflozin 10mg and Rosuvastatin 10mg</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or postmenopausal female patients ;&#xD;
&#xD;
          -  Type 2 diabetes mellitus(HbA1C ≥6.5% - &lt;8.5%)&#xD;
&#xD;
          -  At least 12 weeks of stable dose metformin treatment, FPG&lt;13.2 mmol/l&#xD;
&#xD;
          -  LDL cholesterol &gt;2.5 mmol/l&#xD;
&#xD;
          -  Willing to switch used statin to rosuvastatin 10mg once daily&#xD;
&#xD;
          -  18-75 years of age&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiovascular event&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  exogenous insulin use&#xD;
&#xD;
          -  Creatinin clearance &lt; 60ml/min&#xD;
&#xD;
          -  Alcohol abuse (&gt;4 units/day)&#xD;
&#xD;
          -  AST or ALT elevation (&gt;2.5x upper limit)&#xD;
&#xD;
          -  Contraindication to MR scanning (i.e. pacemaker, metallic foreign body,&#xD;
             claustrophobia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Nieuwdorp, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <results_first_submitted>May 20, 2020</results_first_submitted>
  <results_first_submitted_qc>July 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2020</results_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>D van Raalte</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03074630/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin treatment for 5 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin</title>
          <description>Nine male and 3 postmenopausal female participants were included. One female participant was excluded during the study due to missing data, as we were unable to place a venous catheter during the second hyperinsulinemic clamp, thus we present the analysis for the 11 evaluable participtans.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="50" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma LDL Cholesterol</title>
        <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma LDL Cholesterol</title>
          <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background.</description>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.2" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma HDL Cholesterol</title>
        <description>Change in plasma HDL cholesterol following dapagliflozin</description>
        <time_frame>12 weeks</time_frame>
        <population>5 weeks of dapagliflozin added to rosuvastatin</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma HDL Cholesterol</title>
          <description>Change in plasma HDL cholesterol following dapagliflozin</description>
          <population>5 weeks of dapagliflozin added to rosuvastatin</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="-0.03" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol</title>
        <description>Change in total cholesterol following dapagliflozin</description>
        <time_frame>5 weeks</time_frame>
        <population>treated with 10mg dapagliflozin</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin treatment for 5 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol</title>
          <description>Change in total cholesterol following dapagliflozin</description>
          <population>treated with 10mg dapagliflozin</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.42" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Triglycerides</title>
        <description>Change in plasma Triglycerides following dapagliflozin</description>
        <time_frame>5 weeks</time_frame>
        <population>dapagliflozin treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin treatment for 5 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Triglycerides</title>
          <description>Change in plasma Triglycerides following dapagliflozin</description>
          <population>dapagliflozin treatment</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-0.41" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma FFA</title>
        <description>Change in plasma FFA following dapagliflozin</description>
        <time_frame>5 weeks</time_frame>
        <population>5 weeks of dapagliflozin</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin treatment for 5 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma FFA</title>
          <description>Change in plasma FFA following dapagliflozin</description>
          <population>5 weeks of dapagliflozin</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.04" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cholesterol Fluxes</title>
        <description>Including cholesterol production, cholesterol excretion, cholesterol degradation. Before and after 5 weeks of dapagliflozin on rosuvastatin background.</description>
        <time_frame>5 weeks</time_frame>
        <population>These measurements were conditional, and have not been performed due to the absent change in the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cholesterol Fluxes</title>
          <description>Including cholesterol production, cholesterol excretion, cholesterol degradation. Before and after 5 weeks of dapagliflozin on rosuvastatin background.</description>
          <population>These measurements were conditional, and have not been performed due to the absent change in the primary outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglyceride Fluxes</title>
        <description>Including cholesterol production, cholesterol excretion, cholesterol degradation. Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
        <time_frame>5 weeks</time_frame>
        <population>These measurements were conditional, and have not been performed due to the absent change in the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglyceride Fluxes</title>
          <description>Including cholesterol production, cholesterol excretion, cholesterol degradation. Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
          <population>These measurements were conditional, and have not been performed due to the absent change in the primary outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peripheral Insulin Sensitivity</title>
        <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background, measured as glucose disposal during hyperinsulinemic euglycemic clamp</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peripheral Insulin Sensitivity</title>
          <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background, measured as glucose disposal during hyperinsulinemic euglycemic clamp</description>
          <units>umol/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Fat MRI Spectrum</title>
        <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
        <time_frame>5 weeks</time_frame>
        <population>This measurement was conditional, and has not been performed due to the absent change in the primary outcome. Liver fat content was not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Fat MRI Spectrum</title>
          <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
          <population>This measurement was conditional, and has not been performed due to the absent change in the primary outcome. Liver fat content was not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fecal Microbiome Composition</title>
        <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background, different bacterial strains will be quantified in fresh fecal samples.</description>
        <time_frame>5 weeks</time_frame>
        <population>Sample collection failed. There were not enough samples to perform a proper analysis. Therefore, the few samples that were collected have not been measured and no data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Fecal Microbiome Composition</title>
          <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background, different bacterial strains will be quantified in fresh fecal samples.</description>
          <population>Sample collection failed. There were not enough samples to perform a proper analysis. Therefore, the few samples that were collected have not been measured and no data is available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bile Salt Excretion</title>
        <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
        <time_frame>5 weeks</time_frame>
        <population>This measurement was conditional, and has not been performed due to the absent change in the primary outcome. Since there was no change in plasma cholesterol, this was no longer interesting and samples were not measured</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Bile Salt Excretion</title>
          <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
          <population>This measurement was conditional, and has not been performed due to the absent change in the primary outcome. Since there was no change in plasma cholesterol, this was no longer interesting and samples were not measured</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Glucose Excretion</title>
        <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
        <time_frame>5 weeks</time_frame>
        <population>Subtracted from glucose disposal rate, not separately analyzed in paper</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Glucose Excretion</title>
          <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
          <population>Subtracted from glucose disposal rate, not separately analyzed in paper</population>
          <units>mg/min</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="20" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Sodium Excretion</title>
        <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
        <time_frame>5 weeks</time_frame>
        <population>This measurement was conditional, and has not been performed due to the absent change in the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>5 weeks of dapagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Sodium Excretion</title>
          <description>Before and after 5 weeks of dapagliflozin on rosuvastatin background</description>
          <population>This measurement was conditional, and has not been performed due to the absent change in the primary outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 weeks</time_frame>
      <desc>Patient reported and actively assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events</title>
          <description>5 weeks of dapagliflozin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>genital fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The comparatively small number of participants, the absence of a control group and short follow-up time limit the study and we only included subjects with uncomplicated type 2 diabetes on metformin monotherapy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Erik van Bommel</name_or_title>
      <organization>AmsterdamUMC</organization>
      <phone>+31 20 4444444</phone>
      <email>e.vanbommel@amsterdamumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

